Mesoblast (ASX:MSB) entered an agreement with the US Centers for Medicare & Medicaid Services, enabling access to its US Food and Drug Administration-approved therapy, Ryoncil, according to a Monday filing with the Australian bourse.
The agreement ensures coverage for about 40% of US children with steroid-refractory acute graft versus host disease, with mandatory coverage starting July 1, the filing said.
The therapy is available to both Medicaid and privately insured children, and the first treatments are set to start this week, the filing added.
Shares of the firm fell almost 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.